238 related articles for article (PubMed ID: 17659477)
1. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Chazot PL
Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
[TBL] [Abstract][Full Text] [Related]
2. Safinamide (Newron Pharmaceuticals).
Chazot PL
Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
[TBL] [Abstract][Full Text] [Related]
3. Safinamide for the treatment of Parkinson's disease.
Dézsi L; Vécsei L
Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
[TBL] [Abstract][Full Text] [Related]
4. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
[TBL] [Abstract][Full Text] [Related]
5. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
7. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients.
Liguori C; Mercuri NB; Stefani A; Pierantozzi M
Sleep Med; 2018 Jan; 41():113-114. PubMed ID: 29268951
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
10. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
11. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
12. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.
Leonetti F; Capaldi C; Pisani L; Nicolotti O; Muncipinto G; Stefanachi A; Cellamare S; Caccia C; Carotti A
J Med Chem; 2007 Oct; 50(20):4909-16. PubMed ID: 17824599
[TBL] [Abstract][Full Text] [Related]
13. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs.
Binda C; Wang J; Pisani L; Caccia C; Carotti A; Salvati P; Edmondson DE; Mattevi A
J Med Chem; 2007 Nov; 50(23):5848-52. PubMed ID: 17915852
[TBL] [Abstract][Full Text] [Related]
14. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
15. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Müller T; Foley P
Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
19. Safinamide: first global approval.
Deeks ED
Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
[TBL] [Abstract][Full Text] [Related]
20. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Müller T; Riederer P; Grünblatt E
Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
